✦ LIBER ✦

An economic analysis of erlotinib, docetaxel, pemetrexed and best supportive care as second or third line treatment of non-small cell lung cancer

✍ Scribed by A. Araújo; B. Parente; R. Sotto-Mayor; E. Teixeira; T. Almodôvar; F. Barata; H. Queiroga; C. Pereira; H. Pereira; F. Negreiro; C. Silva

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Araújo A, et al. An economic analysis of

✍ Wojciech Bartminski 📂 Article 📅 2009 🏛 Elsevier ⚖ 146 KB

Araújo A, et al. An economic analysis of

✍ António Araújo 📂 Article 📅 2009 🏛 Elsevier ⚖ 129 KB

PCN52 ECONOMIC ANALYSIS OF ERLOTINIB, DO

✍ F Negreiro; C Pereira; H Pereira; C Silva 📂 Article 📅 2008 🏛 John Wiley and Sons 🌐 English ⚖ 78 KB

Erlotinib or best supportive care for th

✍ Cromwell, Ian; van der Hoek, Kimberly; Malfair Taylor, Suzanne C.; Melosky, Barb 📂 Article 📅 2012 🏛 Elsevier Science 🌐 English ⚖ 396 KB

PCN120 COST-UTILITY OF DOCETAXEL COMPARE

✍ J Rutkowski; B Gwiosda; B Lisiecka; M Wladysiuk; J Lis; R Plisko; P Rys 📂 Article 📅 2009 🏛 John Wiley and Sons 🌐 English ⚖ 81 KB

PCN25 COST-EFFECTIVENESS ANALYSIS OF ERL

✍ Kim, YG; Lee, EK 📂 Article 📅 2010 🏛 John Wiley and Sons 🌐 English ⚖ 65 KB